Nephrocalcinosis clinical trials
The registry lists 22 studies for Nephrocalcinosis across more than 10 countries. 8 are recruiting or about to start. 9 of them are mainly about Nephrocalcinosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Nephrocalcinosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Hospices Civils de Lyon (2) · Calcilytix Therapeutics, Inc., a BridgeBio company (2) · University of Nottingham (1) · University of Utah (1) · Albany Medical College (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Sohag University (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1)
What is being tested here
Drugs under test in Nephrocalcinosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric Onset · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Apr 2027Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients · Institute of Spa and Balneology, public research institution
- Oct 2027Diagnostic Work-up of Nephrocalcinosis in Children · Assiut University
Who these studies take
Of the 4 Nephrocalcinosis studies recruiting now, 0 (0%) set no upper age limit and 4 (100%) stop at 75 or younger. 2 (50%) take children under 18. 0 (0%) are for women only and 1 (25%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (50%) | 2 (50%) |
| 18 | 2 (50%) | 3 (75%) |
| 30 | 1 (25%) | 2 (50%) |
| 40 | 2 (50%) | 3 (75%) |
| 50 | 2 (50%) | 3 (75%) |
| 65 | 2 (50%) | 3 (75%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 22 studies, recruiting or not: 59% stop at 75 or younger and 45% at 65; 77% take children; 0% are for women only and 5% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 12, 2026.
Started recruiting1
- The GranStone TrialNov 10, 2026NCT07828002
Newly registered2
- Diagnostic Work-up of Nephrocalcinosis in ChildrenOct 20, 2026NCT07882355
- Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric OnsetOct 14, 2026NCT07874087
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- The GranStone TrialRecruitingNCT07828002Phase 2/31 country
- Diagnostic Work-up of Nephrocalcinosis in ChildrenNot yet recruitingNCT07882355
- Epidemiology and Risk Factors of Nephrolithiasis and Nephrocalcinosis With Pediatric OnsetEnrolling by invitationNCT078740871 country
- Rifampin in CYP24A1-related Hypercalcemia and HypercalciuriaRecruitingNCT03301038Phase 21 country
- Effective Dosing of Burosumab in XLHRecruitingNCT071835791 country
- Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult PatientsRecruitingNCT07435844Not applicable1 country
- Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?Not yet recruitingNCT072017011 country
- Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University HospitalNot yet recruitingNCT05862207
- Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Active, not recruitingNCT05680818Phase 310 countries
- ADH1 and ADH2 Disease Monitoring Study (DMS)Active, not recruitingNCT0522728713 countries
- Randall's Plaque Study: Pathogenesis and Relationship to NephrolithiasisActive, not recruitingNCT00169806Not applicable1 country
- Natural History of Patients With PH3 and a History of Stone EventsCompletedNCT045425905 countries
- Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D LevelsCompletedNCT04495608Phase 21 country
- The Incidence and the Risk Factors of Nephrocalcinosis in Very Preterm InfantsCompletedNCT043829761 country
- Phenotyping of Primary HyperoxaluriaStatus unknownNCT051078301 country
- The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIHStatus unknownNCT03384121Phase 11 country
- Preterm Infants and NephrocalcinosisCompletedNCT024382671 country
- International Registry for Primary HyperoxaluriaWithdrawnNCT008758231 country
- ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudyStatus unknownNCT02155803Phase 2/31 country
- Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme PrematureStatus unknownNCT01756547Phase 31 country
- Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm InfantsCompletedNCT00249951Phase 31 country
- Renal Tubular Acidosis in Incident Renal Transplant RecipientsStatus unknownNCT012838801 country